KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Integrated psychological resilience and nutritional support improves sleep, emotional wellbeing, inflammation, and clinical recovery in colon cancer: a randomized controlled trial. PMID 41841224 · Psychol Health Med · 2026-Mar-17 The study is an oncology RCT with time-to-event endpoints, but it fails the drug intervention criterion (intervention is non-drug). The phase is also not definitively established as Phase III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial. PMID 41759531 · Cell Rep Med · 2026-Mar-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The effects of a smoking cessation intervention on mortality after a 32.5-year follow-up period: a randomized clinical trial. PMID 41164942 · Am J Epidemiol · 2026-Mar-17 Study is a randomized clinical trial with time-to-event mortality endpoints, but it is a smoking cessation intervention trial (non-drug) and does not provide evidence of being a Phase III/IIIb or Phase II/III oncology trial. The primary intervention is behavioral (smoking cessation program) with bronchodilator/placebo arms, but the drug component (bronchodilator) is not the primary intervention and the trial is not focused on a drug-containing oncology treatment.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men. PMID 41162330 · Clin Infect Dis · 2026-Mar-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment. PMID 41128642 · J Clin Endocrinol Metab · 2026-Mar-17 The study is a Phase III randomized trial of a drug for acromegaly, which is not a human malignant neoplasm. The primary efficacy endpoint is a biochemical response (IGF-I normalization), not a time-to-event endpoint like OS, PFS, or DFS, and there is no indication of Kaplan-Meier analysis or hazard ratios for survival/time-to-event data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Primary Outcomes from the ACT 2 Randomized Trial. PMID 41891028 · medRxiv · 2026-Mar-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. PMID 41528981 · Clin Cancer Res · 2026-Mar-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Valued Living intervention to increase advance care planning and well-being in depressed and anxious adults with advanced cancer: Randomized trial in community oncology clinics. PMID 41848105 · Cancer · 2026-Mar-15 The study is a randomized trial in oncology patients but fails key eligibility criteria: it is not explicitly a Phase III trial, lacks a time-to-event primary efficacy endpoint (OS/PFS/etc.), and does not involve a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Eligibility criteria in phase 3 randomized controlled trials in metastatic non-small cell lung cancer. PMID 41838447 · Cancer · 2026-Mar-15 This is a meta-analysis of eligibility criteria across multiple phase 3 RCTs, not an original report of a single trial's efficacy results. It lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. PMID 41817106 · Cancer · 2026-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy. PMID 41808570 · Cancer · 2026-Mar-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Bowel Cleansing with Mini S-Oral Sulfate Tablet versus the Conventional Oral Sulfate Tablet: A Prospective, Randomized, Investigator-Blinded, Multicenter, Noninferior, Phase 3 Trial. PMID 41306094 · Gut Liver · 2026-Mar-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Parotid-Sparing Versus Conventional Whole Brain Radiation Therapy: A Multi-Institutional Randomized Clinical Trial. PMID 41161645 · Int J Radiat Oncol Biol Phys · 2026-Mar-15 The study is a randomized trial in oncology with original results, but it does not meet all required criteria: it lacks a drug-containing intervention (it compares radiotherapy techniques), it has no time-to-event efficacy endpoint (the primary endpoint is xerostomia score), and the phase is not explicitly stated as Phase III/IIIb or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial. PMID 41106690 · Int J Radiat Oncol Biol Phys · 2026-Mar-15 The report is an original Phase III randomized trial in oncology with human patients and time-to-event endpoints (relapse-free survival, overall survival). However, the intervention is radiation therapy, not a drug-containing intervention. Therefore, it does not meet the criterion of having a drug-containing intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: Phase II CENTAURO-4 trial results. PMID 41099583 · Int J Cancer · 2026-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia]. PMID 41991313 · Zhonghua Xue Ye Xue Za Zhi · 2026-Mar-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. PMID 41830344 · Clin Infect Dis · 2026-Mar-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative efficacy of neoadjuvant short-course versus long-course radiotherapy-based regimens with or without immunotherapy for locally advanced pMMR rectal cancer: a systematic review and network meta-analysis. PMID 41826948 · BMC Med · 2026-Mar-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial. PMID 41826281 · Nat Commun · 2026-Mar-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial. PMID 41796601 · Lancet · 2026-Mar-14 The trial meets criteria for oncology, human, randomized, Phase III, drug intervention, and original result, but the primary efficacy endpoint is ORR, which is not a time-to-event endpoint as required. No time-to-event signal (Kaplan-Meier, HR, or time-to-event outcome) is identified in the abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. PMID 41765025 · Lancet · 2026-Mar-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial. PMID 41833909 · Int J Radiat Oncol Biol Phys · 2026-Mar-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial. PMID 41826895 · BMC Cancer · 2026-Mar-13 The study is a randomized trial in oncology reporting a time-to-event endpoint, but it investigates radiotherapy fractionation schedules, not a drug-containing intervention. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. The primary focus is a biomarker/prognostic analysis, not the reporting of a drug's efficacy in a definitive trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone. PMID 41826282 · Pharmacogenomics J · 2026-Mar-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial. PMID 41824255 · J Patient Rep Outcomes · 2026-Mar-13 The study is part of a Phase III randomized trial (CARTITUDE-4) evaluating a drug intervention (ciltacabtagene autoleucel) in oncology (multiple myeloma). However, this specific abstract reports validation of a patient-reported outcome instrument (MySIm-Q) using trial data, not a time-to-event efficacy outcome (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. Therefore, it does not meet the time-to-event efficacy endpoint criterion for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized controlled phase III trial on continued or paused PD-1 pathway blockade for patients with advanced renal cell carcinoma (JCOG1905, STOP study): a study protocol. PMID 41324490 · Jpn J Clin Oncol · 2026-Mar-13 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer. PMID 41826123 · Eur Urol Focus · 2026-Mar-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The Efficacy and Safety of Enarodustat for the Treatment of Anemia in Hemodialysis-Dependent Chronic Kidney Disease Patients: A Phase 3, Multicenter, Randomized, Active-Comparator (Recombinant Human Erythropoietin), Open-Label Study - The ENARODIAL Study. PMID 41818346 · Am J Nephrol · 2026-Mar-12 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial. PMID 41816796 · Nutr Clin Pract · 2026-Mar-12 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. PMID 41812193 · N Engl J Med · 2026-Mar-12 The record is a Phase 3 randomized oncology trial with a drug intervention and original results. However, the primary efficacy endpoint is a categorical proportion (odds ratio/risk ratio for absence of chemotherapy modifications), not a time-to-event outcome (OS, PFS, DFS, EFS, RFS, TTP, or any Kaplan-Meier/HR analysis). The deterministic review correctly flagged 'no_time_to_event_signal'. Therefore, it does not meet the time-to-event criterion for this adjudication.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial. PMID 41825810 · Int J Radiat Oncol Biol Phys · 2026-Mar-11 The report is a secondary analysis of a Phase III randomized trial, but it focuses on quality-of-life outcomes, not a time-to-event efficacy endpoint required for the cohort.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Who is missing from SGLT-2 inhibitor trials? Implications for drug safety and generalizability: a systematic review and meta-analysis. PMID 41784948 · Expert Opin Drug Saf · 2026-Mar-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study. PMID 41655462 · Eur J Cancer · 2026-Mar-11 This is a formal-result report from a Phase III randomized trial (ARASENS) but presents a secondary safety and dose-intensity analysis. It does not contain a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.) as required for inclusion in the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study. PMID 41001841 · Sleep · 2026-Mar-11 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. PMID 41875364 · Eur J Cardiothorac Surg · 2026-Mar-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg. PMID 41843763 · J Crohns Colitis · 2026-Mar-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evolution of Anti-Vascular Endothelial Growth Factor Clinical Trial Design for Treating Neovascular Age-Related Macular Degeneration. PMID 41822409 · J Vitreoretin Dis · 2026-Mar-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Effect of Motivational Interviewing Based on the COM-B Model on Women's Cervical Cancer Health Beliefs and Participation in Screening: A Single-Blind Randomized Controlled Trial. PMID 41812047 · Cancer Nurs · 2026-Mar-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial. PMID 41807015 · BMJ Open Respir Res · 2026-Mar-10 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Sex as a moderator of the association between cardiorespiratory fitness and depressive symptoms in older adults. PMID 41691469 · J Gerontol B Psychol Sci Soc Sci · 2026-Mar-10 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. PMID 41538748 · J Clin Oncol · 2026-Mar-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Predictors of Skeletal-Related Events and Quality-of-Life Dimensions Among Patients With High-Risk Asymptomatic Bone Metastases With or Without Early Radiation Therapy: Secondary Analysis of a Multicenter Randomized Phase II Clinical Trial. PMID 41825136 · J Natl Compr Canc Netw · 2026-Mar-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms. PMID 41807028 · J Korean Med Sci · 2026-Mar-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical and radiographic outcomes of a novel posterior occlusal splint in adults with temporomandibular joint osteoarthritis: a retrospective case series. PMID 41803814 · BMC Oral Health · 2026-Mar-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Transthyretin amyloid depletion therapy: lessons from the phase 2 trial of coramitug. PMID 41801500 · Heart Fail Rev · 2026-Mar-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. PMID 41741368 · Oncologist · 2026-Mar-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trial. PMID 41795841 · J Natl Cancer Inst · 2026-Mar-07 While the record meets many inclusion criteria (oncology, human, randomized, time-to-event, drug intervention, original result), the specific trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata. The deterministic review note explicitly flags that phase evidence is unclear. Without confirmation of a definitive phase, eligibility cannot be set to true.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma. PMID 41794844 · Nat Commun · 2026-Mar-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Intravenous lidocaine reduces systemic inflammation but not myocardial injury following thoracic surgery for lung cancer: a randomized controlled trial. PMID 41794665 · BMC Anesthesiol · 2026-Mar-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. PMID 41794437 · Lancet · 2026-Mar-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -